share_log

Ascendiant Capital Initiates Coverage On Vivos Therapeutics With Buy Rating, Announces Price Target of $2.5

Ascendiant Capital Initiates Coverage On Vivos Therapeutics With Buy Rating, Announces Price Target of $2.5

Ascendiant Capital以买入评级启动对Vivos Therapeutics的报道,宣布目标股价为2.5美元
Benzinga Real-time News ·  2023/01/17 05:38

Ascendiant Capital analyst Edward Woo initiates coverage on Vivos Therapeutics (NASDAQ:VVOS) with a Buy rating and announces Price Target of $2.5.

Ascendiant Capital分析师爱德华·胡以买入评级开始报道Vivos Therapeutics(纳斯达克股票代码:VVOS),并宣布目标股价为2.5美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发